Efinopegdutide

Efinopegdutide is a long-acting GLP-1/glucagon receptor dual agonist developed for metabolic disorders. It aims to improve blood sugar control and reduce body weight.

In the literature, Efinopegdutide appears most often in work focused on blood sugar, weight loss and metabolism. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.

Because it is catalogued here under powder peptides, Efinopegdutide also shows up in discussions of fat loss. Coverage across those topics varies widely in quality and depth, and much of it is early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.